Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q58F21
UPID:
BRDT_HUMAN
Alternative names:
Cancer/testis antigen 9; RING3-like protein
Alternative UPACC:
Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1; Q7Z4A6; Q8IWI6
Background:
Bromodomain testis-specific protein, also known as Cancer/testis antigen 9 and RING3-like protein, plays a pivotal role in spermatogenesis. It binds specifically to acetylated histones H4K5ac and H4K8ac, facilitating gene activation during meiosis and post-meiosis. This protein is essential for the removal of hyperacetylated histones in the post-meiotic phase and participates in mRNA splicing and 3'-UTR truncation in spermatocytes and spermatids.
Therapeutic significance:
Given its crucial role in spermatogenesis, Bromodomain testis-specific protein is directly linked to Spermatogenic failure 21, an infertility disorder. Understanding the role of this protein could open doors to potential therapeutic strategies for treating infertility related to spermatogenesis defects.